Pegaspargase

證據等級: L5

預測適應症: 10 個

Pegaspargase: From Acute Lymphoblastic Leukemia to Precursor Lymphoblastic Lymphoma/Leukemia

One-Sentence Summary

Pegaspargase (DrugBank DB00059) is a pegylated asparaginase enzyme therapy long used as a component of multi-agent chemotherapy for acute lymphoblastic leukemia (ALL). The TxGNN model predicts it may be effective for precursor lymphoblastic lymphoma/leukemia — a disease spectrum that substantially overlaps with its established use — supported by 50 clinical trials and 20 publications, though this appears to largely reaffirm an already-known indication rather than reveal a novel repurposing opportunity.

Quick Overview

Item	Content
Original Indication	Acute lymphoblastic leukemia (component of multi-agent chemotherapy) — not documented in Danish licensing data, as the drug is not currently marketed in Denmark
Predicted New Indication	Precursor lymphoblastic lymphoma/leukemia
TxGNN Prediction Score	99.96%
Evidence Level	L1
Denmark Market Status	Not Marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (DrugBank MOA query pending). Based on known pharmacological information, pegaspargase is a PEGylated form of E. coli-derived L-asparaginase, an enzyme-based antineoplastic that depletes circulating asparagine — an amino acid that leukemic lymphoblasts cannot synthesize themselves, leading to selective protein-synthesis inhibition and cell death in asparagine-dependent malignant cells.

Precursor lymphoblastic lymphoma/leukemia (encompassing B-ALL, B-lymphoblastic lymphoma, and T-ALL/T-lymphoblastic lymphoma) is generally regarded as the same underlying disease biology as acute lymphoblastic leukemia, differing mainly by the degree of marrow versus extramedullary/nodal involvement at diagnosis. Because asparaginase’s cytotoxic mechanism targets the shared metabolic vulnerability of lymphoblasts regardless of whether disease presents as leukemia or lymphoma, the mechanistic rationale for this “prediction” is strong.

It should be noted, however, that this is not a novel repurposing signal in the conventional sense: pegaspargase (marketed elsewhere as Oncaspar®) is already an established, guideline-standard component of ALL/lymphoblastic lymphoma induction and consolidation regimens internationally. The high TxGNN score most likely reflects the model correctly recovering a known, well-validated drug-disease relationship rather than surfacing a new therapeutic hypothesis. The practical value here lies in confirming Denmark’s current lack of market access to a globally standard-of-care agent for this disease.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00671034	Phase 3	Completed	166	Randomized comparison of calaspargase pegol vs. pegaspargase combined with chemotherapy in newly diagnosed high-risk ALL
NCT01117441	Phase 3	Completed	6,136	International collaborative protocol comparing combination chemotherapy regimens incorporating PEG-asparaginase in children/adolescents with ALL
NCT00819351	Phase 3	Completed	650	NOPHO protocol: intermittent vs. continuous PEG-asparaginase dosing for asparagine depletion in pediatric/young adult ALL
NCT00549848	Phase 3	Completed	600	Total Therapy XVI: high-dose vs. conventional-dose PEG-asparaginase during continuation therapy in ALL
NCT02393859	Phase 3	Completed	111	Blinatumomab consolidation vs. conventional chemotherapy (incl. pegaspargase) in pediatric high-risk relapsed B-precursor ALL
NCT01190930	Phase 3	Active, not recruiting	9,350	Risk-adapted chemotherapy regimens in newly diagnosed standard-risk B-ALL or localized B-lymphoblastic lymphoma
NCT02003222	Phase 3	Active, not recruiting	488	Blinatumomab plus chemotherapy (pegaspargase-containing) vs. induction chemotherapy alone in newly diagnosed BCR-ABL-negative B-ALL
NCT03914625	Phase 3	Active, not recruiting	6,720	Blinatumomab combined with chemotherapy including pegaspargase for standard-risk B-ALL/B-lymphoblastic lymphoma
NCT02716233	Phase 3	Active, not recruiting	2,044	French national protocol optimizing L-asparaginase use in pediatric/adolescent ALL
NCT03959085	Phase 3	Recruiting	5,951	Inotuzumab ozogamicin added to pegaspargase-containing post-induction therapy for high-risk B-ALL

Literature Evidence

PMID	Year	Type	Journal	Key Findings
34228505	2021	Clinical Trial (DFCI 11-001)	Journal of Clinical Oncology	Efficacy and toxicity of pegaspargase vs. calaspargase pegol in childhood ALL
37276451	2023	Clinical Trial (GIMEMA LAL1913)	Blood Advances	Pegaspargase-modified risk-oriented program improves outcomes in adult Ph-negative ALL/lymphoblastic lymphoma
21454191	2011	Clinical Trial	Clinical Lymphoma, Myeloma & Leukemia	Augmented hyper-CVAD with intensified pegaspargase dosing improves salvage therapy outcomes in adult relapsed ALL
27114587	2016	Clinical Trial (COG AALL0232)	Journal of Clinical Oncology	Dexamethasone and high-dose methotrexate improve outcomes in high-risk B-ALL
40163215	2025	Clinical Trial (Phase 2)	International Journal of Hematology	Efficacy, safety, and pharmacokinetics of lyophilized pegaspargase in previously untreated ALL
40109190	2025	Expert Consensus	Haematologica	Panel consensus on recognition, prevention, and management of asparaginase/pegaspargase-associated adverse events in adults
31030380	2019	Review	Drugs	Comprehensive review of pegaspargase in acute lymphoblastic leukaemia
31977001	2020	Review (“How I treat”)	Blood	Practical guidance on managing pegaspargase toxicities in adult ALL
17696798	2007	Review	Expert Opinion on Pharmacotherapy	Pharmacology and clinical role of PEG-asparaginase in acute leukemia
9161659	1997	Review	The Annals of Pharmacotherapy	Early review of pegaspargase chemistry, pharmacology, and clinical activity

Denmark Market Information

Pegaspargase is not currently marketed in Denmark — no Marketing Authorisations (national Laegemiddelstyrelsen or centralised EMA) are recorded in the available regulatory data.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic — enzyme-depleting antineoplastic (L-asparaginase class), mechanistically distinct from DNA-damaging cytotoxics but administered within standard cytotoxic chemotherapy protocols
Myelosuppression Risk	Low to moderate as a standalone agent — asparaginase’s primary dose-limiting toxicities are hypersensitivity, hepatotoxicity, pancreatitis, coagulopathy/thrombosis, and hyperglycemia rather than direct marrow suppression; myelosuppression risk is compounded when combined with other agents in standard multi-drug ALL regimens (per PMID 40109190, 31977001)
Emetogenicity Classification	Low to moderate
Monitoring Items	CBC with differential, liver function (ALT/AST/bilirubin/albumin), coagulation parameters (fibrinogen, antithrombin), lipase/amylase (pancreatitis risk), fasting glucose, triglycerides
Handling Protection	Requires standard cytotoxic/antineoplastic drug handling precautions (PPE, closed-system reconstitution, designated disposal) per institutional hazardous drug handling regulations

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information — key warnings, contraindications, and drug interaction data were not available in the structured safety dataset for this drug.

Supplementary note: Literature evidence independently documents a well-characterized adverse event profile for pegaspargase, including hypersensitivity reactions, hepatotoxicity, pancreatitis, thrombosis/coagulopathy, and hyperglycemia (PMID 40109190, 31977001) — these should inform SmPC review once obtained.

Conclusion and Next Steps

Decision: Hold

Rationale: The clinical trial and literature evidence base for pegaspargase in precursor lymphoblastic lymphoma/leukemia is strong (L1 — multiple completed Phase 3 RCTs), reflecting its already-established role in ALL treatment globally. However, a Blocking data gap (missing TFDA/SmPC warnings and contraindications) prevents completion of the mandatory S1 safety pre-assessment, and the drug currently holds zero Marketing Authorisations in Denmark.

To proceed, the following is needed:

Official SmPC / product label with warnings, contraindications, and drug interaction data (currently blocking)
Confirmed mechanism-of-action documentation from DrugBank
Drug-drug interaction (DDI) data (current query returned no results)
Regulatory pathway assessment for Danish market entry or named-patient/compassionate access, given the drug is not currently authorised in Denmark
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.